Advertisement

Ricerca in clinica e in laboratorio

, Volume 13, Issue 1, pp 33–41 | Cite as

Impact of factor VIII deficiency on clotting factor utilization in the United States

  • Louis M. Aledort
  • Scott H. Goodnight
  • A. Vuaya Rao
  • Jan Schwarz
  • Deborah Whitehurst
  • Sandor S. Shapiro
  • Hemophilia Study Group
Article
  • 21 Downloads

Summary

In a study of 1,551 hemophiliacs over a 4-year period of time, factor VIII utilization was assessed. It is clear that factor VIII usage is a function of severity of disease and therapeutic program. The average amount of factor VIII used per patient was 39.880U/year. Patients seiected for home care, use significantly more than those patients not on home care. As much as 101,000 U/year are used by a small number of patients on prophylaxis. These data can be used in predicting source plasma requirements for annual national use as well as costs.

Key-words

Bleeding Factor VIII deficiency Hemophilia Plasmapheresis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aledort L. M.: The treatment of hemophilia: current management-a physician's manual Medical and Scientific Adviscry Council of the National Hemophilia Foundation, 1978.Google Scholar
  2. 2.
    Aledort L. M.: The availability of plasma products and the care of hemophilia patients— J. Amer. med. Ass.246, 157, 1981.CrossRefGoogle Scholar
  3. 3.
    Aledort L. M., Goodnight S. H.: Hemophilia treatment-its relationship to blood products. in: Progress in hematology. Brown, Grune and Stratton, New York, 1981; vol. XII, p. 125.Google Scholar
  4. 4.
    General Linear Model Procedure: SAS users guide. SAS Institute Inc., Raleigh, North Carolina, 1979.Google Scholar
  5. 5.
    Gilbert M., Aledort L. M. (Eds): Comprehensive care in hemophilia: a team approach— Mt Sinal J. Med.44, 313, 1977.Google Scholar
  6. 6.
    Hershgold E. J., Pool J. G., Pappenhagen A. R.: The potent antihemophilic globulin concentrate derived from a cold insoluble fraction of human plasma: characterization and further data on preparation and clinical trial—J. Lab. clin. Med.67, 23, 1965.Google Scholar
  7. 7.
    National Blood Policy Act: Federal Register 1974, March 8, (no. 47); p. 39.Google Scholar
  8. 8.
    NHLI's Blood Resource Studies: Pilot study of hemophilia treatment in the United States. June 30, 1972; vol. 3.Google Scholar
  9. 9.
    STUDY to evaluate the supply-demand relationships for AHF and PTC through 1980 (contract #1-HB-6-2965): DHEW Publ. #(NH)-77-1274. US Department of Health, Education and Welfare.Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • Louis M. Aledort
    • 1
  • Scott H. Goodnight
    • 1
  • A. Vuaya Rao
    • 1
  • Jan Schwarz
    • 1
  • Deborah Whitehurst
    • 1
  • Sandor S. Shapiro
    • 1
  • Hemophilia Study Group
    • 1
  1. 1.Department of MedicineMount Sinai School of Medicine of the City Univeristy of New YorkNew YorkUSA

Personalised recommendations